CGONCG Oncology, Inc.
What is the market doing?
No clear lean: nothing decisive, though heavily shorted (+13% of shares).
Choppy, but holding above its 200-day average. Oversold (RSI 24). Price is +2% vs its 200-day average.
Insiders were net sellers over the 90 days ending Oct 8, 2026; selling is often routine (taxes, diversification).
Heavily shorted, settled Sep 15, 2026, more than a week of normal trading to cover, a crowded exit.
Against the whole market›
Percentile against every name Ryufin tracks. Higher is better; the tick marks the middle of the market. Context, not one of the checks above.
Where this answer is blind. Insider selling is often routine (taxes, diversification); only cluster buying is a strong tell.
How CGON is trading
CG Oncology, Inc. is +73% over the past year while the S&P 500 is +18%: 55 points ahead of the market.
1-year return · S&P 500 +18%
- vs 200-day average
- +2.1%
vs 200-day average · close to trend
- RSI (14)
- 24
RSI (14) · oversold, sold harder than it has been bought
- Below its 52-week high
- 21%
Below its 52-week high
Details›
- Last close2026-10-09
- $63.86
- 1 monthS&P 500 +2.7%
- −11%
- 1 yearS&P 500 +18%
- +73%
- vs 50-day average$73.19
- −13%
- 52-week high
- $80.66
- 52-week low
- $36.48
- Annualised volatility
- 61%
- Insider buying, net, 6 monthsForms 3/4/5 to 2026-10-08
- $25M
| Year | Return |
|---|---|
| 2026 (year to date) | +54% |
| 2025 | +45% |
| Month | Years | Positive | Average |
|---|---|---|---|
| Jan | 2 | 2 of 2 | +15% |
| Feb | 3 | 2 of 3 | +6.3% |
| Mar | 3 | 1 of 3 | +2.7% |
| Apr | 3 | 1 of 3 | +0.05% |
| May | 3 | 0 of 3 | −10% |
| Jun | 3 | 2 of 3 | +5.1% |
| Jul | 3 | 2 of 3 | +2.7% |
| Aug | 3 | 3 of 3 | +4.9% |
| Sep | 3 | 2 of 3 | +16% |
| Oct | 3 | 1 of 3 | −2.8% |
| Nov | 2 | 1 of 2 | +0.72% |
| Dec | 2 | 0 of 2 | −12% |
End-of-day closes from IEX; the S&P 500 comparison uses SPY over the same window. Prices are a reference point, not a basis for trading decisions.
Biotechnology
The closest names by size in the same industry